Information about Mirabegron
Mirabegron is a beta-3 adrenergic agonist that is used for treatment of overactive bladder syndrome.
Liver safety of Mirabegron
Mirabegron has not been implicated in causing liver enzyme elevations or clinically apparent acute liver injury.
Mechanism of action of Mirabegron
Mirabegron (mir" a beg' ron) is a synthetic beta-3 adrenergic agonist which binds to receptors in the bladder that causes relaxation of the detrusor smooth muscle and results in an increase in the bladder capacity. Mirabegron has been evaluated as therapy of the overactive bladder syndrome, a condition marked by urgency, frequency, nocturia and incontinence that occurs most commonly in older women. Other therapies of overactive bladder include anticholinergics, but these are only partially effective and can have troublesome side effects, particularly in the elderly. In several short term clinical trials, mirabegron was found to increase voided volume and decrease episodes of incontinence and urinary frequency modestly.
FDA approval information for Mirabegron
Mirabegron was approved for use in the United States in 2012 as treatment of overactive bladder with symptoms of urgency, incontinence and frequency. Mirabegron is available as 25 and 50 mg extended release tablets under the brand name Myrbetriq.
Dosage and administration for Mirabegron
The typical dose in adults is 25 to 50 mg orally once daily.
Side effects of Mirabegron
Side effects are not common, but can include nausea, diarrhea, constipation, dizziness, tachycardia, palpitations, hypertension and headache. Rare, but potentially severe side effects include hypersensitivity reactions, angioedema and rash.
- Overactive bladder syndrome agents - darifenacin, fesoterodine, flavoxate, hyoscyamine, mirabegron, oxybutynin, solifenacin, tolterodine, trospium
Cost and Coupons - Mirabegron
- GoodRx compare cost & coupons for Mirabegron
- Find the lowest cost of Mirabegron
- Search for Coupons for Mirabegron
Reviews for Mirabegron
Learn more about Mirabegron
- Dailymed label info
- Scientific articles
- Drug portal Mirabegron
- toxicity info on Mirabegron
- FDA Mirabegron